Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Waive COVID-19 IP rights, poor nations urge

A proposal by the governments of India and South Africa to waive intellectual property protections for COVID-19 vaccines and drugs is being opposed by the US biopharma industry. The proposal, submitted to the World Trade Organization (WTO) Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) last October, called for IP rights on COVID-19 vaccines and medicines to be suspended, to allow for compulsory licensing until the end of the pandemic crisis. World Health Organization director-general Tedros Adhanom Ghebreyesus said in a speech that he backs the proposal. “The flexibilities in the TRIPS agreement are there to be used in emergencies. If not now, then when?” But a group of developed countries including the United States, United Kingdom, Canada, Japan and Norway, as well as the European Union, blocked WTO consideration of the proposal in December. In a letter to US president Joe Biden on 5 March, Michelle McMurry-Heath, president and CEO of the trade association BIO, called the proposal “both a wrong-headed and ineffective means of spurring further efforts at access.” And the lobbying group PHRMA also sent a letter, signed by 30 CEOs, urging the Biden administration to oppose the waiver, saying that eliminating IP protections would undermine the global response to the pandemic. The letter added that COVID-19 vaccine manufacturers are on track to supply 10 billion doses by the end of this year—enough to vaccinate the entire global vaccine-eligible population. Caught in the middle is WTO director-general Ngozi Okonjo-Iweala, who has pressed for a ‘third way’ that “preserves the multilateral rules that encourage research and innovation while promoting licensing agreements to help scale-up manufacturing of medical products,” as she wrote in a Financial Times op-ed on 2 March.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Waive COVID-19 IP rights, poor nations urge. Nat Biotechnol 39, 395 (2021). https://doi.org/10.1038/s41587-021-00905-8

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing